Pilot Study of chemotherapy with Capecitabine,Oxaliplatin and Bevacizumab for pulmonary metastases from colorectal cancer
- Conditions
- Pulmonary metastases from colorectal cancer
- Registration Number
- JPRN-UMIN000004556
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Not provided
1.Body cavity fluid,and it needs drainage 2.Brain metastases or brain cancer 3.With active double cancers 4.With unresectable metastases except for pulmonary metastases 5.With cerebrovascular disease,or history of cerebrovascular disease less than 1year prior to entry 6.Surgery,biopsy with skin incision,or traumatic injury with suture less than 4weeks prior to entry 7.With thrombosis,or history of thrombosis less than 1 year prior to entry 8.Trend of bleeding or coagulation disorder 9.With uncontrolable ulcer 10.With gastrointestinal perforation,or history of gastrointestinal perforation less than 1 year prior to entry 11.With bone fracture 12.With renal disfunction,or proteiun uria 2+ less than 2 weeks prior to entry 13.With uncontrolable hypertension 14.With cardiovascular disease,or myocardinal dysfunction less than 1year prior to entry 15.History of hypersensitivity for test drugs 16.History of adverse event caused by fluoropyrimidine drugs 17.With uncontrorable diarrhea 18.With interstitial pneumonia or pulmonary fibrosis 19.With uncontrorable infection 20.With carcinomatous pleuritis 21.Nursing or pregnant females,or females who are planning to pregnancy 22.Male who are plannning to pregnancy 23.Participation in other clinical trial less than 4weeks prior to entry 24.History of bevacizumab or oxaliplatin use 25.Any other serious medical consition that would preclude study treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method response rate,resection rate of pulmonary metastases,protcol treatment accomplish rate, progression free survival